Abbott (NYSE:ABT) announced that it launched the Jot Dx — its latest insertable cardiac monitor (ICM) — in the U.S.
Jot Dx offers clinicians and hospitals control of the management of the flow of information through a feature that allows the viewing of abnormal heart rhythm data and offers the opportunity to simplify which irregular heart rhythms are recorded with a “key episodes” feature, according to a news release.
Abbott Park, Ill.-based Abbott said the technology allows for remote detection and improved diagnosis accuracy for cardiac arrhythmia in patients. The platform is supported by SyncUP, a personalized service that provides one-on-one training and education to help patients connect to their ICM.
The Jot Dx platform monitors patient cardiac rhythms 24 hours a day, seven days a week and connects to myMerlin, a mobile app designed to transmit data in real-time to clinicians and patients. Abbott said all wireless communication from the myMerlin app is encrypted using “the highest standards in mobile security.”
“Technology can be intimidating, particularly when your heart is relying on it,” Abbott divisional VP of global clinical & regulatory for the company’s cardiac rhythm management business Heidi Hinrichs said in the release. “With Jot Dx ICM, myMerlin, SyncUP and our other technologies, we want people to feel supported, knowledgeable and confident when using them, and ultimately, in control of their care.
“We understand healthcare is not one-size-fits-all and have learned from the people who use our products that a patient-centric approach can lead to a more manageable heart health experience.”